De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Voyager Therapeutics Toekomstige groei
Future criteriumcontroles 0/6
De omzet en winst van Voyager Therapeutics zullen naar verwachting dalen met respectievelijk 11% en 24.1% per jaar. De winst per aandeel zal naar verwachting afnemen met 13.8% per jaar. Het rendement op het eigen vermogen zal naar verwachting -27% in 3 jaar.
Belangrijke informatie
-24.1%
Groei van de winst
-13.8%
Groei van de winst per aandeel
Biotechs winstgroei | 28.6% |
Inkomstengroei | -11.0% |
Toekomstig rendement op eigen vermogen | -27.0% |
Dekking van analisten | Good |
Laatst bijgewerkt | 26 Sep 2024 |
Recente toekomstige groei-updates
Recent updates
Voyager Therapeutics: CNS Player In Early Stages Of A Turnaround
Aug 26Earnings Beat: Voyager Therapeutics, Inc. (NASDAQ:VYGR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 09Lacklustre Performance Is Driving Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Low P/S
Aug 08Voyager: Alzheimer's Clinical Trial Start (VY-TAU01) Strengthens Investment Thesis
Jun 05There's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price Rise
Mar 15Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier
Mar 08What Does The Future Hold For Voyager Therapeutics, Inc. (NASDAQ:VYGR)? These Analysts Have Been Cutting Their Estimates
Mar 04Voyager Therapeutics, Inc. (NASDAQ:VYGR) Surges 45% Yet Its Low P/S Is No Reason For Excitement
Jan 04Voyager stock rises as Pfizer opts to use AAV capsid for neurologic disease target
Oct 04Voyager Therapeutics hires new finance chief
Sep 07Voyager Therapeutics GAAP EPS of -$0.50 misses by $0.02
Aug 04Looking Back In On Voyager Therapeutics
Jun 08Need To Know: Analysts Just Made A Substantial Cut To Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Estimates
May 12Voyager Does A Reboot After First Generation Failures
Mar 25Companies Like Voyager Therapeutics (NASDAQ:VYGR) Could Be Quite Risky
Feb 07Voyager Therapeutics: Another Year, Another Deal
Nov 21Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 54 | -125 | -90 | -83 | 6 |
12/31/2025 | 56 | -119 | -117 | -111 | 9 |
12/31/2024 | 69 | -80 | -30 | -25 | 9 |
6/30/2024 | 144 | 9 | -22 | -18 | N/A |
3/31/2024 | 119 | -3 | 8 | 13 | N/A |
12/31/2023 | 250 | 132 | 75 | 78 | N/A |
9/30/2023 | 158 | 52 | 86 | 89 | N/A |
6/30/2023 | 195 | 96 | 91 | 94 | N/A |
3/31/2023 | 191 | 99 | 74 | 77 | N/A |
12/31/2022 | 41 | -46 | -15 | -13 | N/A |
9/30/2022 | 71 | -17 | 9 | 11 | N/A |
6/30/2022 | 31 | -60 | 4 | 6 | N/A |
3/31/2022 | 32 | -71 | 1 | 2 | N/A |
12/31/2021 | 37 | -71 | -55 | -54 | N/A |
9/30/2021 | 16 | -93 | -92 | -87 | N/A |
6/30/2021 | 132 | 18 | -100 | -91 | N/A |
3/31/2021 | 160 | 39 | -100 | -89 | N/A |
12/31/2020 | 171 | 37 | -109 | -97 | N/A |
9/30/2020 | 197 | 40 | -110 | -98 | N/A |
6/30/2020 | 100 | -61 | -103 | -95 | N/A |
3/31/2020 | 117 | -41 | -113 | -105 | N/A |
12/31/2019 | 104 | -44 | 41 | 49 | N/A |
9/30/2019 | 74 | -54 | 43 | 48 | N/A |
6/30/2019 | 55 | -59 | 47 | 52 | N/A |
3/31/2019 | 12 | -96 | 57 | 61 | N/A |
12/31/2018 | 8 | -88 | -20 | -16 | N/A |
9/30/2018 | 12 | -78 | -10 | -6 | N/A |
6/30/2018 | 11 | -81 | -8 | -5 | N/A |
3/31/2018 | 10 | -74 | N/A | 2 | N/A |
12/31/2017 | 10 | -71 | N/A | -61 | N/A |
9/30/2017 | 6 | -74 | N/A | -60 | N/A |
6/30/2017 | 8 | -59 | N/A | -54 | N/A |
3/31/2017 | 11 | -50 | N/A | -47 | N/A |
12/31/2016 | 14 | -40 | N/A | -42 | N/A |
9/30/2016 | 17 | -34 | N/A | -39 | N/A |
6/30/2016 | 18 | -32 | N/A | -36 | N/A |
3/31/2016 | 20 | -30 | N/A | -33 | N/A |
12/31/2015 | 17 | -38 | N/A | 41 | N/A |
9/30/2015 | 12 | -35 | N/A | 46 | N/A |
6/30/2015 | 7 | -32 | N/A | 50 | N/A |
3/31/2015 | 3 | -30 | N/A | 55 | N/A |
12/31/2014 | N/A | -18 | N/A | -12 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De winst van VYGR zal naar verwachting de komende 3 jaar dalen ( -24.1% per jaar).
Winst versus markt: De winst van VYGR zal naar verwachting de komende 3 jaar dalen ( -24.1% per jaar).
Hoge groeiwinsten: De winst van VYGR zal naar verwachting de komende 3 jaar dalen.
Omzet versus markt: De omzet van VYGR zal naar verwachting de komende 3 jaar dalen ( -11% per jaar).
Hoge groei-inkomsten: De omzet van VYGR zal naar verwachting de komende 3 jaar dalen ( -11% per jaar).
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Er wordt voorspeld dat VYGR binnen 3 jaar verliesgevend zal zijn.